Rapport Therapeutics (RAPP) Liabilities and Shareholders Equity (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $497.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $497.6 million, up 64.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 41.46% YoY), and the FY2025 annual result was $512.4 million, up 62.71% from the prior year.
• Liabilities and Shareholders Equity slipped to $497.6 million in Q1 2026 per RAPP's latest filing, from $512.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $535.3 million in Q3 2025 and troughed at $155.4 million in Q4 2023.
• A 4-year average of $364.5 million and a median of $331.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 102.63% in 2024, then declined 17.51% in 2025.
• A 4-year view of Liabilities and Shareholders Equity shows it stood at $155.4 million in 2023, then surged by 102.63% to $314.9 million in 2024, then jumped by 62.71% to $512.4 million in 2025, then fell by 2.89% to $497.6 million in 2026.
• Business Quant data shows RAPP's Liabilities and Shareholders Equity at $497.6 million in Q1 2026, $512.4 million in Q4 2025, and $535.3 million in Q3 2025.